Intensive care medicine

Cyclarity Therapeutics Announces Clinical Advisory Board

Retrieved on: 
Tuesday, October 17, 2023
MonashHeart, DRS, Intensive care medicine, Biomarker, Monash University, Dean (education), Cardiology, Elias Farkouh, National Board of Health and Welfare (Sweden), Cedars-Sinai Medical Center, Hospital, Coronary care unit, Therapy, VHH, Research, Atherosclerosis, Corporate Affairs, Pharmaceutical industry

Cyclarity Therapeutics, Inc. ( https://cyclaritytx.com ), today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.

Key Points: 
  • Cyclarity Therapeutics, Inc. ( https://cyclaritytx.com ), today announced its newly formed Clinical Advisory Board to guide its clinical development of drug candidate UDP-003 for the treatment and prevention of atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases.
  • Dr. Michael E. Farkouh, Associate Dean for Research and Clinical Trials and Professor of Cardiology at Cedars-Sinai Hospital.
  • Nicholls, Farkouh and Shah working with us to provide strategic guidance over the preparation and execution of our clinical program,” said Mike Kope, Corporate Affairs CEO of Cyclarity.
  • Cyclarity expects to conduct the UDP-003 Phase 1 trial under the direction of Dr. Nicholls and VHH, and is exploring potential lead site and primary PI roles with Drs.

T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii

Retrieved on: 
Thursday, October 12, 2023
Bloodstream infections, Food, Bacteria, Intensive care medicine, Acinetobacter baumannii, Risk, Carbapenem, Mortality, World Health Organization, FDA, CE, Escherichia coli, Catheter, ICU, Regulation of tobacco by the U.S. Food and Drug Administration, Pseudomonas aeruginosa, Patient, Infection, Septic shock, Vaccine, Antibiotics

A. baumannii is a cause of bloodstream infections especially in critically ill patients, which can range from a benign transient bacteremia to septic shock.

Key Points: 
  • A. baumannii is a cause of bloodstream infections especially in critically ill patients, which can range from a benign transient bacteremia to septic shock.
  • In a large study of nosocomial bloodstream infections, A. baumannii was the tenth most common pathogen and has a crude ICU mortality rate of 34.0% to 43.4%.
  • “We are excited about the potential to expand the number of pathogens detected by our FDA-cleared T2Bacteria Panel to include the detection of A. baumannii,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.

EQS-News: New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients

Retrieved on: 
Tuesday, October 17, 2023
EGFR, Mayo Clinic, Physician, Acute kidney injury, Radboud University Nijmegen, AKI, Kidney, Gold, Round Table, Creatinine, Radboud University Medical Center, Diagnosis, Intensive care medicine, Chronic kidney disease, Research, GFR, Patient, Medical imaging, Medical device

PenKid is a kidney function biomarker that correlates with gold standard GFR measurements in stable and acute kidney injury (AKI) patients.

Key Points: 
  • PenKid is a kidney function biomarker that correlates with gold standard GFR measurements in stable and acute kidney injury (AKI) patients.
  • Based on penKid, a new formula was developed to estimate the GFR, outperforming widely used conventional equations based on creatinine alone.
  • Hennigsdorf/Berlin, Germany, October 5, 2023 - Diagnostic company SphingoTec GmbH (“SphingoTec”) announces that a new, improved formula has been developed for estimating the GFR using its kidney function biomarker penKid (1).
  • According to the data, penKid strongly correlates with the measured GFR (mGFR), while the penKid-based formula for estimating GFR performs better than routinely used equations.

Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen

Retrieved on: 
Friday, October 13, 2023
Surgery, Medical Devices, Hospitals, Health, Health Technology, Linda, Multimedia, MASI, Desaturation, De novo, US, University of Utah, De novo gene birth, MD, Ori, Motion, Blood gas tension, Apnea, University, Hyperoxia, Intensive care medicine, American Medical Association, FDA, CE marking, Masimo, Oxygen, Oxygen saturation (medicine), Anesthesia & Analgesia, Pulse, Airway management, Patient, Medical device, Compact Disc manufacturing, RD, Anesthesia, Anesthesiology, Pain management

Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that ORi™, a noninvasive, continuous parameter designed to provide additional insight into a patient’s oxygen status in the moderate hyperoxic range under supplemental oxygen, has been granted a De Novo by the FDA.
  • Enabled by the multi-wavelength Masimo rainbow® Pulse CO-Oximetry platform, ORi is designed for use in conjunction with oxygen saturation (SpO2) to provide increased resolution of changes in oxygenation under supplemental oxygen.
  • View the full release here: https://www.businesswire.com/news/home/20231013679815/en/
    Without ORi, there is no noninvasive way to monitor oxygenation under supplemental oxygen to manage hyperoxia, or higher than normal oxygenation of arterial blood.
  • By convention, SpO2 is limited to an upper limit of 100%, but oxygenation can rise into hyperoxia when supplemental oxygen is administered.

Masimo Receives EU MDR CE Mark for LiDCO® Module for Hemodynamic Monitoring

Retrieved on: 
Monday, October 9, 2023
Medical Devices, Health, Hospitals, Surgery, Health Technology, Cardiology, Southampton General Hospital, Multimedia, Nursing care plan, Hospital, Consultant, Doctor of Philosophy, MASI, BIC, Intelligence, Brain, Anesthesiology, MD, Stroke volume, Mortality, Root, Intensive care medicine, ERAS, FDA, Physiology, CE, Cardiac output, Blood pressure, ICU, OR, Patient, Medical device, Nursing, Anesthesia, Masimo, Neuroscience

The LiDCO BIC module is designed to connect to multi-patient monitoring platforms, like the Masimo Root® Patient Monitoring and Connectivity Hub, to provide advanced hemodynamic monitoring.

Key Points: 
  • The LiDCO BIC module is designed to connect to multi-patient monitoring platforms, like the Masimo Root® Patient Monitoring and Connectivity Hub, to provide advanced hemodynamic monitoring.
  • With this solution, clinicians can easily add LiDCO hemodynamic monitoring – with its one-of-a-kind versatile PulseCO® algorithm – to their Root patient monitoring hubs.
  • For the first time, there is now a solution that can enable hemodynamic monitoring alongside other supported parameters without having a dedicated hemodynamic monitoring box.
  • Combining Masimo rainbow® Pulse CO-Oximetry and LiDCO hemodynamic monitoring brings the potential for significant new insights into patient status.

HemoSonics Wins Medical Device Network Excellence Award in Two Categories

Retrieved on: 
Thursday, October 5, 2023
Hospital, Food, AUC, Business, Intelligence, Journal of Cardiothoracic Surgery, Intensive care medicine, Health, Coagulation, Artificial intelligence, FDA, New product development, Trauma, Cartridge, GlobalData, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Operating, Medical device

DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics, a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards. HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes. Clinicians don't need to wait on test results during a serious life-threatening bleeding event, and, as a result, patients receive optimized interventions as quickly as possible and only when needed.

Key Points: 
  • DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics , a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards .
  • HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.
  • The Medical Device Network Excellence Awards is an independent recognition program powered by the business intelligence of GlobalData .
  • HemoSonics also received an innovative technology contract award from Vizient, opening the door for the System to be adopted by hospitals and academic medical centers across the United States.

EoS Fitness Opens First Fort Worth Location

Retrieved on: 
Thursday, September 28, 2023
Men, Sports, General Sports, Family, Specialty, Consumer, Commercial Building & Real Estate, Construction & Property, Fitness & Nutrition, Retail, Women, Health, Intensive care medicine, Tank, EGYM, Inflammation, Eos, Greater Houston, Chemical oxygen demand, Relaxation, Interior design, DFW

EoS Fitness’ footprint is growing as big as the Texas sky with the opening of its first gym in Fort Worth, the seventh to open in the state this year.

Key Points: 
  • EoS Fitness’ footprint is growing as big as the Texas sky with the opening of its first gym in Fort Worth, the seventh to open in the state this year.
  • Located at 3560 Altamesa Blvd, the new Fort Worth gym is part of the company’s strategic growth, with plans to open 50 new locations in the Greater Houston Area and DFW metroplex by 2028.
  • The national fitness brand already has open gyms throughout Texas with three more gyms scheduled to open by the end of 2023.
  • “We’re welcoming Fort Worth residents to our newest location in the Wedgwood East neighborhood with an expansive gym fully stacked with innovative options for every fitness level,” said Richard Idgar, COO at EoS Fitness.

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Retrieved on: 
Monday, September 18, 2023
Vaccine, European Scientific Cooperative on Phytotherapy, Vaccination, COVID-19, ASX, CSL, Infection, Doctor of Philosophy, Intensive care medicine, Death, Influenza, Hospital, ICU, Conference

The Belgian data highlights how adjuvanted vaccines would not only be cost-effective but could also prevent 6,920 influenza infection, 530 hospitalizations and 66 deaths annually.2

Key Points: 
  • The Belgian data highlights how adjuvanted vaccines would not only be cost-effective but could also prevent 6,920 influenza infection, 530 hospitalizations and 66 deaths annually.2
    SUMMIT, N.J., Sept. 18, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal influenza on hospitals and broader healthcare systems.1,2 These data are being presented in poster sessions at the European Scientific Working Group on Influenza (ESWI) Conference taking place in Valencia, from 17-20 September 2023.
  • "In a world where healthcare systems are laser-focused on enhancing the prevention of infectious diseases, vaccination isn't just an option but an essential tool," said Joaquin Mould-Quevedo, PhD, Global HEOR & Value Strategy Director, CSL Seqirus.
  • "As a global leader in influenza protection, CSL Seqirus recognizes its responsibility to help reduce the burden of flu around the world, and data presented at ESWI provide insight into how enhanced influenza vaccines might ease that burden on French and  Belgian health systems and communities.
  • "1,2
    In France, approximately 2 to 6 million individuals are affected by influenza annually, leading to over 20,000 hospitalizations and 10,000 excess deaths, 90% of which occur in older adults.1 A new analysis spotlights how influenza vaccines can offer a powerful prevention tool that reduces healthcare resource use.1 Findings from a dynamic transmission model indicated that standard-dose quadrivalent influenza vaccines for this demographic could reduce hospitalizations  by 11.1%-30.0% and ICU admissions  by 9.7%-28.7%.1 Additionally, enhanced vaccines are projected to further reduce the strain on hospitals and intensive care units by 10-15%, supporting bed availability during a potential COVID-19 endemic wave.1
    In Belgium, where roughly 62% of older adults received a standard-dose egg-based influenza vaccine between 2015-2019, an analysis was conducted to investigate the potential cost effectiveness of using an adjuvanted quadrivalent influenza vaccine (aQIV).2 Findings from the analysis, based on a static cost-effectiveness model, showed that transitioning to aQIV could prevent 6,920 influenza infections a year that would typically seek medical care, along with 530 hospitalizations and 66 deaths.2 From a cost perspective, aQIV was both cost-effective with an incremental cost of €15,227/QALY when compared to the standard dose and cost-saving compared with the high-dose vaccine.2

EQS-News: Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Retrieved on: 
Saturday, September 16, 2023
ADM, DPP3, Research and development, Sepsis, Radboud University Medical Center, Septic, Organ dysfunction, Biomarker, Septic shock, Intensive care medicine, Plasma, Patient, Risk, Sir Ewan Forbes, 11th Baronet, Medicine, Mortality, Nursing care plan, Congress, Conference, Pharmaceutical industry

Adrenomed is preparing a confirmatory trial

Key Points: 
  • Adrenomed is preparing a confirmatory trial
    Enibarcimab is targeting loss of vascular integrity, a previously unaddressed pathophysiological mechanism [1]
    Adrenomed presenting on individualized precision medicine treatment at the World Sepsis Day Event, Berlin, September 12 [2]
    Hennigsdorf/Berlin (Germany), September 8, 2023 – Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic shock with enibarcimab.
  • New data analyses of the phase II clinical trial AdrenOSS-2 validate the precision medicine approach applied by Adrenomed in the development of its non-neutralizing antibody enibarcimab for the treatment of septic shock.
  • They underpin Adrenomed’s hypothesis that there is an interplay between baseline DPP3 levels and treatment effects of enibarcimab in patients with septic shock.
  • The AdrenOSS-2 trial has marked an important step forward in bringing our precision medicine approach to patients.

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Retrieved on: 
Friday, September 8, 2023
ADM, DPP3, Research and development, Sepsis, Radboud University Medical Center, Septic, Organ dysfunction, Biomarker, Septic shock, Intensive care medicine, Plasma, Patient, Risk, Medicine, Mortality, Poster, Nursing care plan, Congress, Conference, Medical device, Pharmaceutical industry

Adrenomed is preparing a confirmatory trial

Key Points: 
  • Adrenomed is preparing a confirmatory trial
    Enibarcimab is targeting loss of vascular integrity, a previously unaddressed pathophysiological mechanism1
    Adrenomed presenting on individualized precision medicine treatment at the World Sepsis Day Event, Berlin, September 122
    HENNIGSDORF, Germany and BERLIN, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic shock with enibarcimab.
  • New data analyses of the phase II clinical trial AdrenOSS-2 validate the precision medicine approach applied by Adrenomed in the development of its non-neutralizing antibody enibarcimab for the treatment of septic shock.
  • They underpin Adrenomed’s hypothesis that there is an interplay between baseline DPP3 levels and treatment effects of enibarcimab in patients with septic shock.
  • The AdrenOSS-2 trial has marked an important step forward in bringing our precision medicine approach to patients.